 |
245 Diseases |  |
54 Trials |
|
54 Trials |  |
1419 News |  |
| «12345678910111213...2021» |
- | carmustine / Generic mfg.
Journal: Carmustine wafer implantation for supratentorial glioblastomas, IDH-wildtype in "extreme" neurosurgical conditions. (Pubmed Central) - Jun 21, 2023
Carmustine wafer implantation during the surgical resection of a newly diagnosed supratentorial glioblastoma, IDH-wildtype is safe and efficient in patients?>?80
- | Journal: Assessment of Stem Cell Transplant Eligibility in Recipients with Oral Foci of Infection: Appropriate Conditioning Regimens. (Pubmed Central) - Jun 21, 2023
Carmustine wafer implantation during the surgical resection of a newly diagnosed supratentorial glioblastoma, IDH-wildtype is safe and efficient in patients?>?80 Transplant is a valid option in patients with oral foci of infections undergoing various autologous and allogeneic transplant protocols when time is of the essence, even at myeloablative dose intensities.
- | melphalan / Generic mfg., cyclophosphamide / Generic mfg., carmustine / Generic mfg.
Journal: Immunoablative therapy followed by autologous hematopoietic stem cell transplantation as the first-line disease-modifying therapy in patients with multiple sclerosis. (Pubmed Central) - Jun 20, 2023
Transplant is a valid option in patients with oral foci of infections undergoing various autologous and allogeneic transplant protocols when time is of the essence, even at myeloablative dose intensities. Our case series of 6 patients shows that AHSCT is a promising therapeutic approach to slow down the rapid progression of clinical disability in MS patients with a good safety profile.
- | Depocyte (liposomal cytarabine) / Mundipharma, Leadiant Biosci, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial primary completion date: Auto Stem Cell Transplant for Lymphoma Patients (clinicaltrials.gov) - Jun 5, 2023
P2, N=150, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Our case series of 6 patients shows that AHSCT is a promising therapeutic approach to slow down the rapid progression of clinical disability in MS patients with a good safety profile. Trial primary completion date: Apr 2023 --> Sep 2023
- || Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
Trial completion date, Trial primary completion date, Combination therapy: XPORT-GBM-029: A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma (clinicaltrials.gov) - May 30, 2023
P1/2, N=474, Active, not recruiting, Sponsor: Karyopharm Therapeutics Inc
Trial primary completion date: Apr 2023 --> Sep 2023 Trial completion date: Jan 2023 --> Apr 2024 | Trial primary completion date: Jan 2023 --> Jul 2023
- | Starasid (cytarabine ocfosfate) / Nippon Kayaku
Enrollment closed, Enrollment change, Trial primary completion date, Gene therapy: Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant (clinicaltrials.gov) - May 30, 2023
P1/2, N=11, Active, not recruiting, Sponsor: AIDS Malignancy Consortium
Trial completion date: Jan 2023 --> Apr 2024 | Trial primary completion date: Jan 2023 --> Jul 2023 Recruiting --> Active, not recruiting | N=18 --> 11 | Trial primary completion date: Dec 2024 --> Jan 2023
- | temozolomide / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date: hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) (clinicaltrials.gov) - May 25, 2023
P2, N=16, Recruiting, Sponsor: Leland Metheny
Recruiting --> Active, not recruiting | N=18 --> 11 | Trial primary completion date: Dec 2024 --> Jan 2023 Not yet recruiting --> Recruiting | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
- | Venclexta (venetoclax) / Roche, AbbVie
New trial: Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL (clinicaltrials.gov) - May 18, 2023
P=N/A, N=52, Not yet recruiting, Sponsor: Ruijin Hospital
- | thiotepa / Generic mfg.
Journal: Long term results with thiotepa containing regimen (TECAM) for autologous stem cell transplantation. (Pubmed Central) - May 9, 2023
Despite a higher proportion of frail patients, the newer cohort's outcomes were favorable, driven by better lymphoma control pre-transplant. In the DLBCL cohort, ECOG-PS was more prognostic than achieving a CR pre-ASCT, a finding that is relevant to the optimal selection of patients to different treatment options in the era of chimeric antigen receptor (CAR-T) availability.
- | vadacabtagene leraleucel (JCAR015) / BMS
Trial completion date, Trial primary completion date: High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - May 3, 2023
P1, N=17, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
In the DLBCL cohort, ECOG-PS was more prognostic than achieving a CR pre-ASCT, a finding that is relevant to the optimal selection of patients to different treatment options in the era of chimeric antigen receptor (CAR-T) availability. Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Apr 2023 --> Apr 2024
- carmustine / Generic mfg.
Preapproval medical products in patients with the diagnosis of metastatic uveal melanoma. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_6571;
However, the number of patients with MUM who received IMPs through EA was small (2.6%) and should be improved. EA should remain a viable option for patients who do not fit the trial requirements or do not have realistic access to a trial site.
- | Mustargen (mechlorethamine) / Recordati
Trial completion date, Trial primary completion date, Metastases: SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells (clinicaltrials.gov) - Apr 25, 2023
P1, N=10, Recruiting, Sponsor: General Oncology, Inc.
EA should remain a viable option for patients who do not fit the trial requirements or do not have realistic access to a trial site. Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
- Folliculotropic Mycosis Fungoides: Current Guidance and Experience from Clinical Practice (Level 3 - Room 320) - Apr 24, 2023 - Abstract #WCD2023WCD_3356;
Advanced forms assume characteristics similar to classic MF, whilst early stages present in a wide range of clinical forms (acneiform lesions, follicular-like keratoses, erythematous patches). As for therapeutic options, in absence of specific guidelines, a high number of treatments are described in clinical practice, with variable results.
- | Duoenda (mitoxantrone liposomal) / CSPC Pharma
New trial: Modified BEAM Regimen for T Cell Lymphoma Underwent ASCT (clinicaltrials.gov) - Apr 18, 2023
P=N/A, N=122, Not yet recruiting, Sponsor: First Affiliated Hospital Xi'an Jiaotong University
- | Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Enrollment open: Targeting Pediatric Brain Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) (clinicaltrials.gov) - Apr 6, 2023
P1, N=20, Recruiting, Sponsor: Washington University School of Medicine
As for therapeutic options, in absence of specific guidelines, a high number of treatments are described in clinical practice, with variable results. Not yet recruiting --> Recruiting
- | carmustine / Generic mfg.
Retrospective data, Journal, Surgery: Recurrent high grade glioma surgery with carmustine wafers implantation: a long-term nationwide retrospective study. (Pubmed Central) - Mar 30, 2023
Not yet recruiting --> Recruiting OS of patients with recurrent HGG that underwent surgery with CW implantation is better in case of prolonged delay between the two resections and, for the patients who had RT and TMZ before and after CW implantation.
- | Simulect (basiliximab) / Novartis, 90Y basiliximab - National Cancer Institute / Bethesda
Trial completion date: Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma (clinicaltrials.gov) - Mar 21, 2023
P1, N=25, Active, not recruiting, Sponsor: City of Hope Medical Center
OS of patients with recurrent HGG that underwent surgery with CW implantation is better in case of prolonged delay between the two resections and, for the patients who had RT and TMZ before and after CW implantation. Trial completion date: Dec 2022 --> Dec 2023
- | Simulect (basiliximab) / Novartis, 90Y basiliximab - National Cancer Institute / Bethesda
Trial completion date: Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Mar 20, 2023
P1, N=20, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Dec 2022 --> Dec 2023 Trial completion date: Dec 2022 --> Dec 2023
- carmustine / Generic mfg.
Porcine brain-derived hydrogel carriers for intratumoral administration of cellular immunotherapies enhances anti-tumor potential in post-resection GBM (Section 35; Poster Board #18) - Mar 14, 2023 - Abstract #AACR2023AACR_2082;
Intracranial administration has been shown to be both safe and effective in delivery of other anti- cancer drugs in GBM, with one example being Gliadel, involving the placement of carmustine chemotherapy-loaded wafers into the post-resection space for sustained release into local brain tissue...We have developed a mouse model of GBM resection and recurrence to evaluate the efficacy of hydrogel-delivered CAR T cell treatment after resection surgery to capitalize on a currently underutilized treatment window. This injectable scaffold will support an immediate clinical need by supporting delivery, expansion, and actuation of CAR T function within the solid tumor microenvironment without the challenges of peripheral delivery to a specialized organ system.
- | carmustine / Generic mfg.
Journal: Intracranial nanomedicine-gel with deep brain- penetration for glioblastoma therapy. (Pubmed Central) - Mar 13, 2023
This injectable scaffold will support an immediate clinical need by supporting delivery, expansion, and actuation of CAR T function within the solid tumor microenvironment without the challenges of peripheral delivery to a specialized organ system. The system consists of ?222
- | Retrospective data, Journal: Comparative Efficacy and Safety of Beam and Team Conditioning Regimens for Autologous Stem Cell Transplantation in Lymphoma Patients. (Pubmed Central) - Feb 27, 2023
The 2 regimens may provide similar overall survival outcomes and have a comparable safety profile. Although the BEAM regimen may be associated with longer progression-free survival times, the difference may be covered by the similar survival after ASCT.
- | cyclophosphamide / Generic mfg., etoposide IV / Generic mfg., carmustine / Generic mfg.
Trial completion date, Trial primary completion date: Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma (clinicaltrials.gov) - Feb 21, 2023
P1, N=25, Active, not recruiting, Sponsor: City of Hope Medical Center
Although the BEAM regimen may be associated with longer progression-free survival times, the difference may be covered by the similar survival after ASCT. Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
- Jakafi (ruxolitinib) / Novartis, Incyte
COMPLETE REMISSION AFTER RELAPSE FOLLOWING ALLOGENIC STEM CELL TRANSPLANTATION IN A PATIENT WITH PERIPHERAL T NON-HODGKIN LYMPHOMA UNDERGOING EXTRACORPOREAL PHOTOPHERESIS (ePoster Area) - Feb 11, 2023 - Abstract #EBMT2023EBMT_1852;
The exact trigger trough which GvL was stimulated remains unclear, however there is a temporal correlation between the start of ECP and achivevement disease control. Even though it remains speculative, the immunomodulatory effect of ECP may have induced GvL, through reversion of T-cell exhaustion or even inducing anti-tumor activity.
- thiotepa / Generic mfg., carmustine / Generic mfg.
IMPACT OF THIOTEPA DOSE-INTENSITY IN PATIENTS WITH PRIMARY LARGE B-CELL LYMPHOMA OF THE CENTRAL NERVOUS SYSTEM (PCNSL) UNDERGOING AUTOLOGOUS TRANSPLANTATION (AUTOHCT) WITH THIOTEPA/CARMUSTINE (TT-BCNU) CONDITIONING (ePoster Area) - Feb 11, 2023 - Abstract #EBMT2023EBMT_1830;
In this registry analysis in patients with PCNSL undergoing TT-BCNU conditioning, we found no statistically significant advantage of higher thiotepa dose-intensity (20mg/kg), when compared to 10mg/kg dose in terms of NRM, relapse, PFS or OS. These findings have potential pharmacoeconomic implications for HCT centers.
- IDENTIFICATION OF PULMONARY AND CLINICAL RISK FACTORS IN PATIENTS WITH LYMPHOMA CONDITIONED WITH BEAM AND TEAM BEFORE AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (ePoster Area) - Feb 11, 2023 - Abstract #EBMT2023EBMT_1824;
In summary, we have identified clinical risk factors and abnormalities in pulmonary function tests associated with worse outcome in patients conditioned with BEAM compared to TEAM before auto-HSCT. Our data suggest TEAM conditioning as a valid alternative for patients with DLCOcSB ?60% of predicted, age >65 years old, HCT-CI score ?5 and/or KPS ?80%.
- BE-EAM HIGH-DOSE CHEMOTHERAPY FOLLOWED BY ASCT: A SINGLE CENTER EXPERIENCE (ePoster Area) - Feb 11, 2023 - Abstract #EBMT2023EBMT_1619;
Background: BEAM (carmustine, etoposide, cytarabine, and melphalan) is used as the most accepted preparation regimen before autologous bone marrow transplantation (ASCT) in patients with relapsed/refractory non Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL)...The preparatory regimen consisted of bendamustine on day -5 and -4 (160-200 mg/m2/d) cytarabine daily from day -6 to day -3 (75 mg/m2 every 12 hours), etoposide daily from day -6 to day -3 (150 mg/m2 every 12 hours) and melphalan on day -2 (100-140mg/m2)... Be-EAM conditioning regimen followed by ASCT seems to be is active with tolerable toxicity in the treatment of patients with advanced lymphoid malignancies, and can be used safely as an alternative to BEAM regimen.
- lomustine / Generic mfg., cyclophosphamide / Generic mfg., etoposide IV / Generic mfg.
LOMUSTINE, ETOPOSIDE AND CYCLOPHOSPHAMIDE IN CONDITIONING REGIMEN FOR LYMPHOMAS: THE EXPERIENCE OF A BRAZILIAN INSTITUTION (ePoster Area) - Feb 11, 2023 - Abstract #EBMT2023EBMT_1609;
Although longer follow-up time is required, LEC proved to be a secure protocol, with higher overall survival rates than protocols used previously in our environment. The LEC protocol proves to be an option to traditional conditioning regimens and may be an alternative to cytarabine protocols or in situations where frequently used medications are lacking.
- Campath (alemtuzumab) / Sanofi
SINGLE CENTRE REVIEW OF THE OUTCOME, MORBIDITY AND HEALTH RESOURCE UTILISATION USING BEAM-ALEMTUZUMAB CONDITIONING IN LYMPHOID MALIGNANCIES; A BASIS FOR IMPLEMENTING CHANGE (ePoster Area) - Feb 11, 2023 - Abstract #EBMT2023EBMT_1602;
Chemo-refractory DLBCL can now be treated with CAR-T therapy and PTCy conditioned alloSCT updated at ASH2022 (BMT CTN Protocol 1703/1801 PROGRESS III) confirmed lower viral infection rates (62% versus 95%) and GvH with preserved survival. This supports our planned change from alemtuzumab to PTCy based conditioning and provides a baseline against which to assess new regimens.
- melphalan / Generic mfg., fludarabine IV / Generic mfg.
COMPARISON OF FLUDARABINE/MELPHALAN(FM140) WITH FLUDARABINE/MELPHALAN/BCNU(FBM110) IN PATIENTS WITH RELAPSED/REFRACTORY AML UNDERGOING ALLOGENEIC TRANSPLANTATION (ePoster Area) - Feb 11, 2023 - Abstract #EBMT2023EBMT_1591;
We speculate that the reduced dose of melphalan is compensated by the addition of the second alkylating agent (BCNU) in FBM110 without increasing toxicity. Future studies should address the efficacy of melphalan containing regimens in combination with other drugs and/or using different dosing.
- A REAL-WORLD EXPERIENCE IN THE ADEQUATION OF CONDITIONING CHEMOTHERAPY FOR AUTOLOGOUS TRANSPLANTATION IN LYMPHOMA PATIENTS WITHOUT CD34 CRYOPRESERVATION (ePoster Area) - Feb 11, 2023 - Abstract #EBMT2023EBMT_1048;
In our experience, conditionings for ASCTin lymphoma patients, adjusted for a non-cryopreserved strategy offer at least similar or even better results than the cryopreserved strategy. Prospective studies are warranted.
- | Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute
Trial completion date, Trial primary completion date, Combination therapy: Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jan 31, 2023
P1, N=30, Recruiting, Sponsor: Case Comprehensive Cancer Center
Prospective studies are warranted. Trial completion date: Feb 2023 --> Jun 2023 | Trial primary completion date: Dec 2022 --> Jun 2023
- | Zynlonta (loncastuximab tesirine-lpyl) / Overland ADCT BioPharma
Enrollment change, Trial withdrawal, Combination therapy: Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Jan 13, 2023
P1, N=0, Withdrawn, Sponsor: Fred Hutchinson Cancer Center
Trial completion date: Feb 2023 --> Jun 2023 | Trial primary completion date: Dec 2022 --> Jun 2023 N=20 --> 0 | Not yet recruiting --> Withdrawn
- | sorafenib / Generic mfg.
Journal: SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase. (Pubmed Central) - Jan 13, 2023
Based on our results, the combination of sorafenib and carmustine (BCNU), a selective inhibitor of GSR, remarkably hamper tumor growth by enhancing ferroptotic cell death in vivo. In conclusion, we describe that SLC27A5 serves as a suppressor in sorafenib resistance and promotes sorafenib-triggered ferroptosis via restraining the NRF2/GSR pathway in HCC, providing a potential therapeutic strategy for overcoming sorafenib resistance.
- | Zynlonta (loncastuximab tesirine-lpyl) / Overland ADCT BioPharma
Trial initiation date, Combination therapy: Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Jan 6, 2023
P1, N=20, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Center
In conclusion, we describe that SLC27A5 serves as a suppressor in sorafenib resistance and promotes sorafenib-triggered ferroptosis via restraining the NRF2/GSR pathway in HCC, providing a potential therapeutic strategy for overcoming sorafenib resistance. Initiation date: Dec 2022 --> Apr 2023
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: High-dose chemotherapy and autologous stem cell transplantation in primary lymphomatoid granulomatosis of the central nervous system. (Pubmed Central) - Dec 25, 2022
Here, the clinical courses and treatments of four primary CNS-LG patients in analogy to aggressive CNS-lymphomas including methotrexate, thiotepa, cytarabine, carmustine, and rituximab are presented. This is the first report on high-dose chemotherapy with CNS-directed drugs and autologous blood stem cell transplantation in primary CNS-LG.
- | Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment closed, IO biomarker: Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Dec 22, 2022
P3, N=302, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
This is the first report on high-dose chemotherapy with CNS-directed drugs and autologous blood stem cell transplantation in primary CNS-LG. Recruiting --> Active, not recruiting
- melphalan / Generic mfg., busulfan / Generic mfg., carmustine / Generic mfg.
Hematopoietic Stem Cell Transplantation Activity for Lymphoma: A Multicentric Study By the Transplantation and Cellular Therapy Mexican Working Group. () - Dec 16, 2022 - Abstract #TCTASTCTCIBMTR2023TCT_ASTCT_CIBMTR_1162;
For relapsed patients, autologous transplantation remains the best option, the lack of carmustine was not an obstacle for favorable outcomes. The prognosis for refractory patients was dismal independently of the type of transplant.
- Incidence of Early Toxicities and Mortality after Four Types of Conditioning Regimens for Autologous Hematopoietic Cell Transplantation in Patients with Lymphoma: Impact of National Drug Shortages in a Resource-Constrained Country () - Dec 16, 2022 - Abstract #TCTASTCTCIBMTR2023TCT_ASTCT_CIBMTR_832;
Carmustine-based conditioning regimens seemed to be less toxic and safer. BeEAM was associated with inferior OS due to increased late-onset TRM.
- | carmustine / Generic mfg.
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Therapeutic Targeting of Sex Differences in Pediatric Brain Tumor Glycolysis (clinicaltrials.gov) - Dec 12, 2022
P=N/A, N=2, Terminated, Sponsor: Washington University School of Medicine
BeEAM was associated with inferior OS due to increased late-onset TRM. N=15 --> 2 | Trial completion date: May 2034 --> Nov 2022 | Recruiting --> Terminated | Trial primary completion date: May 2026 --> Nov 2022; Low accrual
- ||| Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
Enrollment closed, Combination therapy: XPORT-GBM-029: A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma (clinicaltrials.gov) - Dec 12, 2022
P1/2, N=474, Active, not recruiting, Sponsor: Karyopharm Therapeutics Inc
N=15 --> 2 | Trial completion date: May 2034 --> Nov 2022 | Recruiting --> Terminated | Trial primary completion date: May 2026 --> Nov 2022; Low accrual Recruiting --> Active, not recruiting
- | Mustargen (mechlorethamine) / Recordati
Trial completion date, Trial primary completion date, Metastases: SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells (clinicaltrials.gov) - Dec 8, 2022
P1, N=10, Recruiting, Sponsor: General Oncology, Inc.
Recruiting --> Active, not recruiting Trial completion date: May 2024 --> Dec 2024 | Trial primary completion date: May 2024 --> Dec 2024
- || Bexxar (iodine I 131 tositumomab) / GSK, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Retrospective data, Review, Journal: Quantitative evaluation of therapy options for relapsed/refractory diffuse large B-cell lymphoma: A model-based meta-analysis. (Pubmed Central) - Dec 6, 2022
Moreover, with respect to association therapy, there was a strong correlation between the 6-month PFS and 2-year OS. The findings of this study provide the necessary quantitative information for clinical practice and clinical trial design for the treatment of r/rDLBCL.
- carmustine / Generic mfg.
Longitudinal Analysis of the Cerebral Cortex in a Bcnu-treated Rat Model of Cortical Dysplasia (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1524;
Our results suggest that CD is very subtle in the early stages of development, yet progresses over time to frank macroscopic and microscopic abnormalities in this animal model. The temporal evolution of morphologic changes of CD should be taken into consideration for the development of better diagnostic tools for the detection of CD in humans.
- | carmustine / Generic mfg.
Trial primary completion date: Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases (clinicaltrials.gov) - Nov 17, 2022
P2, N=28, Recruiting, Sponsor: Thomas Jefferson University
The temporal evolution of morphologic changes of CD should be taken into consideration for the development of better diagnostic tools for the detection of CD in humans. Trial primary completion date: Aug 2022 --> Dec 2023
- | cisplatin / Generic mfg., temozolomide / Generic mfg., carmustine / Generic mfg.
Journal: MicroRNAs, Key Regulators in Glioma Progression as Potential Therapeutic Targets for Chinese Medicine. (Pubmed Central) - Nov 16, 2022
In this paper, the mechanisms through which microRNAs regulate the sensitivity of gliomas to therapeutic drugs are described, and traditional Chinese medicine that can suppress gliomas through microRNAs are discussed. This review aims to provide new insights into the traditional Chinese medicine treatment of gliomas.
- ||||| carmustine / Generic mfg.
Clinical: Is carmustine necessary? This nationwide multicenter study also by #TCTMX led by @PerlaRcp assessed the outcome of lymphoma patients after transplantation in an environment without access to BEAM. Saturday posters #Lymsm #BMTsm #ASH22 https://t.co/4D3rOd16h7 2/ (Twitter) - Nov 12, 2022
- | lomustine / Generic mfg., temozolomide / Generic mfg., carmustine / Generic mfg.
Journal: CRISPR/Cas9-induced knockout reveals the role of ABCB1 in the response to temozolomide, carmustine and lomustine in glioblastoma multiforme. (Pubmed Central) - Nov 9, 2022
Interestingly, loss of ABCB1 also affected the response to the lipophilic drug carmustine. These findings show that ABCB1 is not only relevant at the blood-brain barrier, but also in the tumor cells diminishing success of chemotherapy.
- | Retrospective data, Journal: The incidence of severe oral mucositis in patients undergoing different conditioning regimens in haematopoietic stem cell transplantation. (Pubmed Central) - Nov 8, 2022
Severe oral mucositis was associated with myeloablative TBI, methotrexate and melphalan in combination with methotrexate and in BEAM. Use of PTCy was preferable over methotrexate to prevent oral mucositis.
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Trial primary completion date, Combination therapy: P+R-ICE: Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Nov 8, 2022
P2, N=65, Recruiting, Sponsor: University of Southampton
Use of PTCy was preferable over methotrexate to prevent oral mucositis. Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2023 --> Oct 2024
- A Retrospective, Matched Paired Analysis Comparing GBM/GBC Versus BEAM/Beac Conditioning Regimen for Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_6585;
Objective: Since BCNU was in short supply across China, we explored alternative conditioning regimens gemcitabine, busulfan combined with melphalan/cyclophosphamide (GBM/GBC) followed by ASCT in lymphoma patients (Bone Marrow Transplant...Herein, we compared the safety and efficacy of GBM/GBC versus carmustine, etoposide, cytarabine combined with melphalan/cyclophosphamide (BEAM/BEAC) conditioning regimen for autologous stem cell transplantation (ASCT) in non-Hodgkin’s lymphoma (NHL)... In this retrospective, matched paired analysis, our results demonstrate that GBM/GBC conditioning regimens with ASCT are feasible with tolerable toxicity, which appears be an alternative to the classical BEAM/BEAC conditioning regimens for ASCT in the treatment of NHL.